IDiyas

For the Inventor, By the Inventor

Fishers, IN, United States of America

Jose Eduardo Lopez

USPTO Granted Patents = 16 

 

 

Average Co-Inventor Count = 4.3

ph-index = 4

Forward Citations = 66(Granted Patents)


Company Filing History:

goldMedal16 out of 4,442 
 
Eli Lilly and Company
 patents

Years Active: 2002-2025

Loading Chart...
Loading Chart...
Loading Chart...
16 patents (USPTO):
1. 12404298 - Glucocorticoid receptor agonists (2025-09-02),
2. 11787834 - Glucocorticoid receptor agonists (2023-10-17),
3. 10836773 - 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds (2020-11-17),
4. 10752632 - 6-fluoro 2-methylbenzo[d]thiazol-5-yl compounds (2020-08-25),
5. 9522923 - Selective BACE1 inhibitors (2016-12-20),
6. 8889856 - Tetrahydropyrrolothiazine compounds (2014-11-18),
7. 8772282 - Tetrahydropyrrolothiazine compounds (2014-07-08),
8. 8629270 - Tetrahydropyrrolothiazine compounds (2014-01-14),
9. 7943795 - Vitamin D receptor modulators (2011-05-17),
10. 7932284 - Indole sulfonamide modulators of progesterone receptors (2011-04-26),
11. 7595403 - Benzisothiazol-3-one-carboxylic acid amides as phospholipase inhibitors (2009-09-29),
12. 7414063 - Inhibitors of Akt (protein kinase B) (2008-08-19),
13. 7250430 - Thiophene-and thiazolesulfonamides as antineoplastic agents (2007-07-31),
14. 7217727 - Phospholipase inhibitors (2007-05-15),
15. 7084170 - Thiophene-amd thiazolesulfonamides as antineoplastic agents (2006-08-01),

Title: Jose Eduardo Lopez – Pioneering Innovator in Pharmaceutical Research

Introduction:

Jose Eduardo Lopez, a distinguished inventor based in Fishers, IN (US), has made significant contributions to the field of pharmaceutical research with his groundbreaking inventions. With a total of 15 patents to his name, Lopez's work has been instrumental in the development of novel treatments for autoimmune and inflammatory diseases.

Latest Patents:

Among his recent patents, Lopez has introduced Glucocorticoid receptor agonists, which are compounds aimed at treating autoimmune and inflammatory conditions such as atopic dermatitis and rheumatoid arthritis. Additionally, his invention of 6-fluoro-2-methylbenzo[d]thiazol-5-yl compounds shows promise in the treatment of neurodegenerative diseases like Alzheimer's.

Career Highlights:

Lopez is a key figure at Eli Lilly and Company, a leading pharmaceutical organization known for its innovative research and development initiatives. His expertise in medicinal chemistry and drug discovery has propelled him to the forefront of the industry, earning him acclaim for his inventive spirit and commitment to advancing healthcare solutions.

Collaborations:

In his research endeavors, Lopez has collaborated closely with esteemed colleagues such as Ho-Shen Lin and Michael Enrico Richett. Together, they have synergized their talents and expertise to push the boundaries of scientific innovation, resulting in the development of cutting-edge therapies with the potential to transform patient care.

Conclusion:

Jose Eduardo Lopez's career exemplifies the essence of innovation and ingenuity in the realm of pharmaceutical research. Through his dedication to pioneering new treatments for complex medical conditions, Lopez continues to shape the landscape of healthcare with his inventive spirit and unwavering commitment to advancing scientific knowledge.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…